|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
CA1271477A
(en)
|
1983-11-18 |
1990-07-10 |
John F. Gerster |
1h-imidazo[4,5-c]quinolin-4-amines
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
|
|
ATE102631T1
(de)
|
1988-11-11 |
1994-03-15 |
Medical Res Council |
Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
US6716580B2
(en)
|
1990-06-11 |
2004-04-06 |
Somalogic, Inc. |
Method for the automated generation of nucleic acid ligands
|
|
US5853984A
(en)
|
1990-06-11 |
1998-12-29 |
Nexstar Pharmaceuticals, Inc. |
Use of nucleic acid ligands in flow cytometry
|
|
EP0533838B1
(en)
|
1990-06-11 |
1997-12-03 |
NeXstar Pharmaceuticals, Inc. |
Nucleic acid ligands
|
|
US5874218A
(en)
|
1990-06-11 |
1999-02-23 |
Nexstar Pharmaceuticals, Inc. |
Method for detecting a target compound in a substance using a nucleic acid ligand
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US6280932B1
(en)
|
1990-06-11 |
2001-08-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands to lectins
|
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
|
US5763177A
(en)
|
1990-06-11 |
1998-06-09 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
US6001577A
(en)
|
1998-06-08 |
1999-12-14 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
US5789163A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Enzyme linked oligonucleotide assays (ELONAS)
|
|
US6465189B1
(en)
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Systematic evolution of ligands by exponential enrichment: blended selex
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
US5226575A
(en)
|
1991-11-21 |
1993-07-13 |
Scott Faust |
Pneumatic mortar dispenser with flex release
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US6608201B2
(en)
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US5798340A
(en)
|
1993-09-17 |
1998-08-25 |
Gilead Sciences, Inc. |
Nucleotide analogs
|
|
US6458539B1
(en)
|
1993-09-17 |
2002-10-01 |
Somalogic, Inc. |
Photoselection of nucleic acid ligands
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5843732A
(en)
|
1995-06-06 |
1998-12-01 |
Nexstar Pharmaceuticals, Inc. |
Method and apparatus for determining consensus secondary structures for nucleic acid sequences
|
|
JP2000503639A
(ja)
|
1995-12-22 |
2000-03-28 |
ブリストル―マイヤーズ スクイブ カンパニー |
分枝ヒドラゾンのリンカー類
|
|
US5922695A
(en)
|
1996-07-26 |
1999-07-13 |
Gilead Sciences, Inc. |
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
|
|
DE59708838D1
(de)
|
1996-08-30 |
2003-01-09 |
Jens Peter Fuerste |
Spiegelselektion und spiegelevolution von nucleinsäuren
|
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
|
US20030054360A1
(en)
|
1999-01-19 |
2003-03-20 |
Larry Gold |
Method and apparatus for the automated generation of nucleic acid ligands
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
DK2283867T3
(da)
|
1999-06-25 |
2014-06-10 |
Immunogen Inc |
Fremgangsmåder til behandling ved anvendelse af anti-ErbB antistof-maytansinoidkonjugater
|
|
US6506887B1
(en)
|
1999-07-29 |
2003-01-14 |
Somalogic, Incorporated |
Conditional-selex
|
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
|
US20050020525A1
(en)
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
DE20014503U1
(de)
|
2000-08-22 |
2001-01-11 |
Siemens AG, 80333 München |
Fertigungsstraßenabschnitt
|
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
UA74593C2
(en)
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
|
US20060142202A1
(en)
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US20030175950A1
(en)
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
|
ATE452655T1
(de)
|
2001-06-10 |
2010-01-15 |
Noxxon Pharma Ag |
Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
|
|
AU2775402A
(en)
|
2001-06-29 |
2003-01-02 |
Medimolecular Pty Ltd |
Nucleic acid ligands to complex targets
|
|
WO2003094836A2
(en)
|
2001-10-12 |
2003-11-20 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
DE60230340D1
(de)
|
2001-11-16 |
2009-01-22 |
3M Innovative Properties Co |
N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
|
|
KR100718371B1
(ko)
|
2001-11-27 |
2007-05-14 |
애나디스 파마슈티칼스, 인코포레이티드 |
３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
|
|
WO2003057145A2
(en)
|
2001-12-31 |
2003-07-17 |
Guilford Pharmaceuticals Inc. |
SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
WO2003105780A2
(en)
|
2002-06-18 |
2003-12-24 |
Epigenesis Pharmaceuticals, Inc. |
A dry powder oligonucleotide formulation, preparation and its uses
|
|
ATE481985T1
(de)
|
2002-07-03 |
2010-10-15 |
Ono Pharmaceutical Co |
Immunpotenzierende zusammensetzungen
|
|
SI1545613T1
(sl)
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
EP1413316A1
(en)
|
2002-09-27 |
2004-04-28 |
Bruno Robert |
Bifunctional conjugates or fusion proteins
|
|
JP2006513212A
(ja)
|
2002-12-20 |
2006-04-20 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリール／ヘタリール置換されたイミダゾキノリン
|
|
CA2508660C
(en)
|
2002-12-23 |
2013-08-20 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US20050036951A1
(en)
|
2003-01-09 |
2005-02-17 |
Arizeke Pharmaceuticals, Inc. |
Methods of treating lung diseases
|
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
|
WO2004071459A2
(en)
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
|
EP2289559B1
(en)
|
2003-02-20 |
2014-02-12 |
Seattle Genetics, Inc. |
Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
CA2537450C
(en)
|
2003-09-05 |
2012-04-17 |
Anadys Pharmaceuticals, Inc. |
Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
|
|
AR046172A1
(es)
|
2003-10-03 |
2005-11-30 |
3M Innovative Properties Co |
Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
|
|
RU2426734C2
(ru)
|
2003-10-03 |
2011-08-20 |
Зм Инновейтив Пропертиз Компани |
Пиразолопиридины и их аналоги
|
|
SG149828A1
(en)
|
2003-10-03 |
2009-02-27 |
3M Innovative Properties Co |
Alkoxy substituted imidazoquinolines
|
|
WO2005034979A2
(en)
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
ITMI20032121A1
(it)
|
2003-11-04 |
2005-05-05 |
Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm |
Procedimento per la preparazione di imiquimod e suoi intermedi
|
|
DK1725249T3
(en)
*
|
2003-11-06 |
2014-03-17 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugating to ligands.
|
|
WO2005067500A2
(en)
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
|
NZ549903A
(en)
|
2004-03-26 |
2010-04-30 |
Astrazeneca Ab |
9-substituted 8-oxoadenine compound
|
|
JP2008506683A
(ja)
*
|
2004-07-18 |
2008-03-06 |
コーリー ファーマシューティカル グループ， リミテッド |
先天免疫応答を誘導するための方法および組成物
|
|
ES2579805T3
(es)
*
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
CA2586913A1
(en)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
|
HUE025749T2
(en)
*
|
2004-12-30 |
2016-04-28 |
Meda Ab |
Use of Imiquimod to treat skin metastases from breast cancer
|
|
CN101128431B
(zh)
*
|
2005-02-24 |
2011-05-25 |
詹森药业有限公司 |
作为钾离子通道打开剂的喹啉衍生物
|
|
CN101155932A
(zh)
|
2005-04-14 |
2008-04-02 |
默克专利有限公司 |
基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
|
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
|
WO2006116423A2
(en)
|
2005-04-26 |
2006-11-02 |
Eisai Co., Ltd |
Compositions and methods for cancer immunotherapy
|
|
CN101217967B
(zh)
|
2005-05-04 |
2014-09-10 |
诺松制药股份公司 |
镜像异构体的新用途
|
|
KR101498834B1
(ko)
*
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
|
HRP20080053A2
(hr)
|
2005-07-01 |
2009-08-31 |
Medarex |
Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
|
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
JP2009506790A
(ja)
|
2005-09-07 |
2009-02-19 |
メディミューン，エルエルシー |
毒素とコンジュゲートしたｅｐｈ受容体抗体
|
|
ZA200803029B
(en)
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
|
WO2007038658A2
(en)
*
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
WO2008004948A1
(en)
|
2006-07-05 |
2008-01-10 |
Astrazeneca Ab |
8-oxoadenine derivatives acting as modulators of tlr7
|
|
EP2061814B1
(en)
|
2006-10-27 |
2012-06-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
CN101568531B
(zh)
|
2006-12-21 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
Mglur5受体拮抗剂的多晶型物
|
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
AU2008227128B2
(en)
|
2007-02-07 |
2012-12-06 |
The Regents Of The University Of California |
Conjugates of synthetic TLR agonists and uses therefor
|
|
JP5394246B2
(ja)
*
|
2007-03-30 |
2014-01-22 |
ジェネンテック， インコーポレイテッド |
抗体及びイムノコンジュゲートとこれらの使用方法
|
|
JP5400763B2
(ja)
|
2007-05-08 |
2014-01-29 |
アストラゼネカ・アクチエボラーグ |
免疫調節特性を有するイミダゾキノリン類
|
|
US20090123467A1
(en)
|
2007-07-31 |
2009-05-14 |
The Johns Hopkins University |
Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
|
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
|
PL2644192T3
(pl)
|
2007-09-28 |
2017-09-29 |
Pfizer Inc. |
Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek
|
|
CN101909624A
(zh)
|
2008-01-15 |
2010-12-08 |
麦达股份公司 |
用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌
|
|
AU2009207287B2
(en)
|
2008-01-25 |
2014-09-11 |
Gavish-Galilee Bio Applications Ltd |
Targeting of innate immune response to tumor site
|
|
BRPI0907907A2
(pt)
|
2008-02-07 |
2015-07-28 |
Univ California |
Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7
|
|
SI2644204T1
(sl)
|
2008-03-18 |
2017-08-31 |
Genentech, Inc. |
Kombinacije konjugata protitelo proti HER2-zdravilo in pertuzumaba
|
|
US8772243B2
(en)
|
2008-08-20 |
2014-07-08 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
|
|
EP3133086B1
(en)
|
2008-09-26 |
2018-08-01 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
|
|
US8895702B2
(en)
|
2008-12-08 |
2014-11-25 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
|
|
BRPI0923305B1
(pt)
|
2008-12-09 |
2019-01-22 |
Gilead Sciences Inc |
moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
|
|
BRPI1006141B8
(pt)
|
2009-01-12 |
2021-05-25 |
Cytomx Therapeutics Llc |
composições de anticorpo modificado, métodos para preparar e usar as mesmas
|
|
US8383768B2
(en)
|
2009-05-07 |
2013-02-26 |
Immunocellular Therapeutics, Ltd. |
CD133 epitopes
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
US20110077263A1
(en)
|
2009-09-29 |
2011-03-31 |
University Of Southern California |
Methods and Compositions of Toll-Like Receptor (TLR) Agonists
|
|
HUE037159T2
(hu)
|
2009-11-24 |
2018-08-28 |
Medimmune Ltd |
Targetált kötõdõ ágensek B7-H1 ellen
|
|
WO2011084726A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
WO2011084725A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
ES2608475T3
(es)
|
2010-04-13 |
2017-04-11 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a cd27 humana y usos de los mismos
|
|
WO2011150264A2
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Synthetic nanocarrier combination vaccines
|
|
KR20130108295A
(ko)
|
2010-08-13 |
2013-10-02 |
베일러 리서치 인스티튜트 |
항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
|
|
NZ608673A
(en)
|
2010-10-01 |
2015-04-24 |
Univ Pennsylvania |
Therapeutic use of a tlr agonist and combination therapy
|
|
US20140044709A1
(en)
*
|
2010-12-09 |
2014-02-13 |
Genentech, Inc. |
Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
|
|
JP5985510B2
(ja)
|
2011-01-12 |
2016-09-06 |
ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｔｏｌｌ様受容体調節薬としての置換ベンゾアゼピン
|
|
SG10201608138RA
(en)
|
2011-02-01 |
2016-11-29 |
Genmab As |
Human antibodies and antibody-drug conjugates against cd74
|
|
AR085633A1
(es)
|
2011-03-08 |
2013-10-16 |
Baylor Res Inst |
Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
|
|
EP3403672A1
(en)
|
2011-04-20 |
2018-11-21 |
Medlmmune, LLC |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
SG194216A1
(en)
|
2011-04-21 |
2013-11-29 |
Origenis Gmbh |
Heterocyclic compounds as kinase inhibitors
|
|
UY34032A
(es)
|
2011-04-21 |
2012-11-30 |
Origenis Gmbh |
Nuevos inhibidores de quinasa
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
TWI835048B
(zh)
|
2011-08-01 |
2024-03-11 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
|
ES2623013T3
(es)
|
2011-08-11 |
2017-07-10 |
Huntsman Advanced Materials Americas Llc |
Método para producir compuestos de benzoxazina
|
|
US9308253B2
(en)
|
2011-09-19 |
2016-04-12 |
The Johns Hopkins University |
Cancer immunotherapy
|
|
WO2013063258A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US10344261B2
(en)
|
2011-11-09 |
2019-07-09 |
Ascend Biopharmaceuticals Ltd |
Immunomodulatory conjugates
|
|
WO2013166110A1
(en)
|
2012-05-02 |
2013-11-07 |
Yale University |
Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
|
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
WO2014022758A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
|
|
US8968742B2
(en)
|
2012-08-23 |
2015-03-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
|
|
US10000482B2
(en)
|
2012-10-19 |
2018-06-19 |
Origenis Gmbh |
Kinase inhibitors
|
|
US9637491B2
(en)
|
2012-10-19 |
2017-05-02 |
Origenis Gmbh |
Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
SG11201605296SA
(en)
|
2014-01-10 |
2016-07-28 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for treating her2 positive tumors
|
|
EA201692512A1
(ru)
|
2014-06-25 |
2017-07-31 |
Селекта Байосайенсиз, Инк. |
Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CN107074958A
(zh)
|
2014-07-09 |
2017-08-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗‑pd‑l1组合
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN105732635A
(zh)
|
2014-12-29 |
2016-07-06 |
南京明德新药研发股份有限公司 |
一类Toll样受体7激动剂
|
|
JP6141568B1
(ja)
|
2015-09-01 |
2017-06-07 |
大鵬薬品工業株式会社 |
新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
|
|
US10821127B2
(en)
|
2015-11-09 |
2020-11-03 |
Shaperon Inc. |
Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
EP3641771A4
(en)
|
2017-06-23 |
2020-12-16 |
Birdie Biopharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
|
US20210214354A1
(en)
|
2018-09-07 |
2021-07-15 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
|
JP2022516093A
(ja)
|
2018-12-26 |
2022-02-24 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
癌の治療のための免疫調節薬の組み合わせおよび方法
|
|
JP2022525216A
(ja)
|
2019-03-15 |
2022-05-11 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
癌の治療のための免疫調節組成物および方法
|
|
CA3192776A1
(en)
|
2020-08-26 |
2022-03-03 |
Lixin Li |
Cancer treatment with tlr agonist
|